Title : Patient reported outcomes of GLP 1/GIP agonist use for lipedema: Results from a survey based study
Abstract:
Lipedema is a chronic condition characterized by disproportionate fat accumulation, inflammation, and pain, predominantly affecting women. Traditional treatments focus on symptom management, but emerging therapies, such as GLP-1/GIP receptor agonists like semaglutide and tirzepatide, offer potential benefits beyond weight loss. These medications have demonstrated anti-inflammatory effects, improved metabolic health, and enhanced mobility in other conditions. However, their specific impact on lipedema remains under explored. This study aims to investigate the experiences of lipedema patients using GLP-1/GIP agonists, focusing on perceived benefits or limitations.
